Global Patent Index - EP 1407049 A4

EP 1407049 A4 20050323 - HISTONE DEACETYLASE AND METHODS OF USE THEREOF

Title (en)

HISTONE DEACETYLASE AND METHODS OF USE THEREOF

Title (de)

HISTON-DEACETYLASE UND VERFAHREN ZUR VERWENDUNG DAVON

Title (fr)

HISTONE-DEACETYLASE ET PROCEDES D'UTILISATION CORRESPONDANTS

Publication

EP 1407049 A4 20050323 (EN)

Application

EP 02742174 A 20020617

Priority

  • US 0219258 W 20020617
  • US 29922801 P 20010619

Abstract (en)

[origin: WO02102316A2] The present invention provides nucleic acid molecules that encode histone deacetylase, as well as recombinant vectors and host cells that include the subject nucleic acid molecules. Also provided are histone deacetylase polypeptide compositions. The histone deacteylase nucleic acid molecules are useful in a variety of diagnostic and therapeutic applications, which are also provided.

IPC 1-7

C12Q 1/68; C12N 9/00; C12N 9/14; C12N 1/20; C12N 15/00; C07H 21/04; C07K 16/00

IPC 8 full level

C12N 9/16 (2006.01); A61K 38/00 (2006.01)

CPC (source: EP US)

C12N 9/16 (2013.01 - EP US); A61K 38/00 (2013.01 - EP US); C07K 2319/00 (2013.01 - EP US)

Citation (search report)

  • [X] WO 0142437 A2 20010614 - AXYS PHARM INC [US], et al
  • [X] KAO H-Y ET AL: "ISOLATION OF A NOVEL HISTONE DEACETYLASE REVEALS THAT CLASS I AND CLASS II DEACETYLASES PROMOTE SMRT-MEDIATED REPRESSION", GENES AND DEVELOPMENT, COLD SPRING HARBOR LABORATORY PRESS, NEW YORK, US, vol. 14, 1 January 2000 (2000-01-01), pages 55 - 66, XP000981426, ISSN: 0890-9369
  • [XD] DATABASE GENBANK 28 August 1998 (1998-08-28), "Homo sapiens 12q13.1 PAC RPCI5-1057I20 (Roswell Park Cancer Institute Human PAC library) complete sequence", XP002301427, retrieved from NCBI Database accession no. AC004466
  • [XA] PENN L Z: "APOPTOSIS MODULATORS AS CANCER THERAPEUTICS", CURRENT OPINION IN INVESTIGATIONAL DRUGS, CURRENT DRUGS, LONDON, GB, vol. 2, no. 5, May 2001 (2001-05-01), pages 684 - 692, XP008018765, ISSN: 0967-8298
  • [X] WEIDLE U H ET AL: "INHIBITION OF HISTONE DEACETYLASES: A NEW STRATEGY TO TARGET EPIGENETIC MODIFICATIONS FOR ANTICANCER TREATMENT", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 20, May 2000 (2000-05-01), pages 1471 - 1485, XP001098720, ISSN: 0250-7005
  • [X] SAWA H ET AL: "Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad.", BRAIN TUMOR PATHOLOGY. 2001, vol. 18, no. 2, 2001, pages 109 - 114, XP009038432, ISSN: 1433-7398
  • See references of WO 02102316A2

Citation (examination)

  • WO 03006652 A2 20030123 - METHYLGENE INC [CA]
  • WO 0058473 A2 20001005 - CURAGEN CORP [US], et al
  • FISCHLE W. ET AL: "The emerging role of class II histone deacetylases", BIOCHEMISTRY AND CELL BIOLOGY, vol. 79, 2001, pages 337 - 348, XP008025333
  • FISCHLE W. ET AL: "Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 38, 21 September 2001 (2001-09-21), pages 35826 - 35835
  • FISCHLE W. ET AL: "A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 17, 23 April 1999 (1999-04-23), pages 11713 - 11720, XP002159645

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 02102316 A2 20021227; WO 02102316 A3 20030424; AU 2002315229 A1 20030102; EP 1407049 A2 20040414; EP 1407049 A4 20050323; US 2003143712 A1 20030731; US 2008233581 A1 20080925; US 7488587 B2 20090210; US 7745173 B2 20100629

DOCDB simple family (application)

US 0219258 W 20020617; AU 2002315229 A 20020617; EP 02742174 A 20020617; US 1327708 A 20080111; US 17555902 A 20020617